The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis

E-ISSN： 1873-4286|18|11|1502-1511

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.11, 2012-04, pp. : 1502-1511

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

By Ranganathan Prabha

Pharmacogenomics, Vol. 6, Iss. 5, 2005-07 ,pp. : 481-490

Future Medicine

Access to resources Recommend Favorite

A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients

By Fu Bo Lunt Mark Galloway James Dixon Will Hyrich Kimme Symmons Deborah

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 2, 2013-03 ,pp. : 461-476

Taylor & Francis Ltd

Access to resources Recommend Favorite

Tumor Necrosis Factor-a Blockade in Rheumatoid Arthritis: Responders Vs Non Responders

Medicinal Chemistry Reviews - Online, Vol. 1, Iss. 3, 2004-07 ,pp. : 361-368

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs

By Avouac J Allanore Y

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 7, 2008-05 ,pp. : 1121-1128

Informa Healthcare

Access to resources Recommend Favorite

The Case of Tumour Necrosis Factor-α Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis

By Sørensen Jan

PharmacoEconomics, Vol. 23, Iss. 3, 2005-01 ,pp. : 289-298

Adis International

Access to resources Recommend Favorite